Circulating tumor cells: detection, molecular profiling and future prospects

References

• Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev.19(3–4), 193–383 (2000).
   Google Scholar
• Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother. Pharmacol.43(Suppl.), S3–S10 (1999).
   PubMedGoogle Scholar
• Coman DR, deLong RP, MccUtcheon M. Studies on the mechanisms of metastasis; the distribution of tumors in various organs in relation to the distribution of arterial emboli. Cancer Res.11(8), 648–651 (1951).
   PubMedGoogle Scholar
• Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the ‘leukemic phase’ of solid cancers. Trends Mol. Med.12(3), 130–139 (2006).
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol.7(5), 704–710 (1995).
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Critical determinants of metastasis. Semin. Cancer Biol.12(2), 89–96 (2002).
   PubMed Web of Science ®Google Scholar
• Okegawa T, Noda H, Kato M et al. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate44(3), 210–218 (2000).
   PubMedGoogle Scholar
• Abbruzzese JL, Abbruzzese MC, Hess KR et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J. Clin. Oncol.12(6), 1272–1280 (1994).
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Angiogenesis and cancer metastasis. Cancer J.6(Suppl. 2), S134–S141 (2000).
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg. Oncol. Clin. N. Am.10(2), 257–269, vii–viiii (2001).
   PubMedGoogle Scholar
• Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer3(6), 453–458 (2003).
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol.3(1), 53–57 (2002).
   PubMed Web of Science ®Google Scholar
• Paget S. The distribution of secondary growths in cancer of the breast. Lancet1, 571–573 (1889).
   Google Scholar
• Kang Y, Massague J. Epithelial–mesenchymal transitions: twist in development and metastasis. Cell118(3), 277–279 (2004).
   PubMed Web of Science ®Google Scholar
• Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs6(1), 3–18 (1995).
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature410(6824), 50–56 (2001).
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer2(3), 161–174 (2002).
   PubMed Web of Science ®Google Scholar
• Janda E, Lehmann K, Killisch I et al. Ras and TGF-β cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol.156(2), 299–313 (2002).
   PubMed Web of Science ®Google Scholar
• Leptin M, Grunewald B. Cell shape changes during gastrulation in Drosophila. Development110(1), 73–84 (1990).
   PubMed Web of Science ®Google Scholar
• Thiery JP. Epithelial–mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol.15(6), 740–746 (2003).
   PubMed Web of Science ®Google Scholar
• Berx G, Cleton-Jansen AM, Nollet F et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J.14(24), 6107–6115 (1995).
   PubMed Web of Science ®Google Scholar
• Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res.62(6), 1613–1618 (2002).
   PubMed Web of Science ®Google Scholar
• Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer34(3), 255–268 (2002).
   PubMed Web of Science ®Google Scholar
• Yoshiura K, Kanai Y, Ochiai A et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl Acad. Sci. USA92(16), 7416–7419 (1995).
   PubMed Web of Science ®Google Scholar
• Brabletz T, Jung A, Hermann K et al. Nuclear overexpression of the oncoprotein β-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract.194(10), 701–704 (1998).
   PubMed Web of Science ®Google Scholar
• Batlle E, Sancho E, Franci C et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol.2(2), 84–89 (2000).
   PubMed Web of Science ®Google Scholar
• Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann. Surg. Oncol.12(6), 488–496 (2005).
   PubMed Web of Science ®Google Scholar
• Rosivatz E, Becker I, Specht K et al. Differential expression of the epithelial–mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am. J. Pathol.161(5), 1881–1891 (2002).
   PubMed Web of Science ®Google Scholar
• Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res.66(9), 4549–4552 (2006).
   PubMed Web of Science ®Google Scholar
• Soo K, O’Rourke MP, Khoo PL et al. Twist function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo. Dev. Biol.247(2), 251–270 (2002).
   PubMed Web of Science ®Google Scholar
• Hotz B, Arndt M, Dullat S et al. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin. Cancer Res.13(16), 4769–4776 (2007).
   PubMed Web of Science ®Google Scholar
• Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res.66(17), 8319–8326 (2006).
   PubMed Web of Science ®Google Scholar
• Meng S, Tripathy D, Frenkel EP et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res.10(24), 8152–8162 (2004).
   PubMed Web of Science ®Google Scholar
• Naumov GN, MacDonald IC, Chambers AF, Groom AC. Solitary cancer cells as a possible source of tumour dormancy? Semin. Cancer Biol.11(4), 271–276 (2001).
   PubMed Web of Science ®Google Scholar
• Al-Mehdi AB, Tozawa K, Fisher AB et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med.6(1), 100–102 (2000).
   PubMed Web of Science ®Google Scholar
• Klement H, St Croix B, Milsom C et al. Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. Am. J. Pathol.171(4), 1342–1351 (2007).
   Google Scholar
• Nanda A, Karim B, Peng Z et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc. Natl Acad. Sci. USA103(9), 3351–3356 (2006).
   PubMed Web of Science ®Google Scholar
• Seaman S, Stevens J, Yang MY et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell11(6), 539–554 (2007).
   PubMed Web of Science ®Google Scholar
• St Croix B, Sheehan C, Rak JW et al. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol.142(2), 557–571 (1998).
   PubMed Web of Science ®Google Scholar
• Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res.40(7), 2281–2287 (1980).
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res.66(23), 11089–11093 (2006).
   PubMed Web of Science ®Google Scholar
• Tarin D, Price JE, Kettlewell MG et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res.44(8), 3584–3592 (1984).
   PubMed Web of Science ®Google Scholar
• Tarin D, Vass AC, Kettlewell MG, Price JE. Absence of metastatic sequelae during long-term treatment of malignant ascites by peritoneo-venous shunting. A clinico-pathological report. Invasion Metastasis4(1), 1–12 (1984).
   Google Scholar
• Scadden DT. The stem-cell niche as an entity of action. Nature441(7097), 1075–1079 (2006).
   PubMed Web of Science ®Google Scholar
• Ridell B, Landys K. Incidence and histopathology of metastases of mammary carcinoma in biopsies from the posterior iliac crest. Cancer44(5), 1782–1788 (1979).
   Google Scholar
• Mansi JL, Gogas H, Bliss JM et al. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet354(9174), 197–202 (1999).
   PubMed Web of Science ®Google Scholar
• Redding WH, Coombes RC, Monaghan P et al. Detection of micrometastases in patients with primary breast cancer. Lancet2(8362), 1271–1274 (1983).
   PubMed Web of Science ®Google Scholar
• Pantel K, Alix-Panabieres C. The clinical significance of circulating tumor cells. Nat. Clin. Pract. Oncol.4(2), 62–63 (2007).
   PubMedGoogle Scholar
• Morgan TM, Lange PH, Vessella RL. Detection and characterization of circulating and disseminated prostate cancer cells. Front. Biosci.12, 3000–3009 (2007).
   Google Scholar
• Boyum A, Lovhaug D, Tresland L, Nordlie EM. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand. J. Immunol.34(6), 697–712 (1991).
   PubMed Web of Science ®Google Scholar
• Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett.253(2), 180–204 (2007).
   PubMed Web of Science ®Google Scholar
• Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am. J. Pathol.156(1), 57–63 (2000).
   PubMed Web of Science ®Google Scholar
• Ellis WJ, Pfitzenmaier J, Colli J et al. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology61(2), 277–281 (2003).
   PubMedGoogle Scholar
• Witzig TE, Bossy B, Kimlinger T et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin. Cancer Res.8(5), 1085–1091 (2002).
   PubMed Web of Science ®Google Scholar
• Loberg RD, Fridman Y, Pienta BA et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia6(4), 302–309 (2004).
   Google Scholar
• Moreno JG, Miller MC, Gross S et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology65(4), 713–718 (2005).
   PubMed Web of Science ®Google Scholar
• Goeminne JC, Guillaume T. Detection of circulating tumor by reverse transcriptase polymerase chain reaction. J. Clin. Oncol.18(17), 3196–3197 (2000).
   Google Scholar
• Schoenfeld A, Luqmani Y, Smith D et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res.54(11), 2986–2990 (1994).
   PubMed Web of Science ®Google Scholar
• Silva JM, Rodriguez R, Garcia JM et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut50(4), 530–534 (2002).
   PubMed Web of Science ®Google Scholar
• Willipinski-Stapelfeldt B, Riethdorf S, Assmann V et al. Changes in cytoskeletal protein composition indicative of an epithelial–mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin. Cancer Res.11(22), 8006–8014 (2005).
   PubMed Web of Science ®Google Scholar
• Fehm T, Braun S, Muller V et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer107(5), 885–892 (2006).
   PubMed Web of Science ®Google Scholar
• Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer6(11), 835–845 (2006).
   PubMed Web of Science ®Google Scholar
• Gerhard M, Juhl H, Kalthoff H et al. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J. Clin. Oncol.12(4), 725–729 (1994).
   PubMed Web of Science ®Google Scholar
• Ghossein RA, Scher HI, Gerald WL et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J. Clin. Oncol.13(5), 1195–1200 (1995).
   PubMed Web of Science ®Google Scholar
• Kaplan JC, Kahn A, Chelly J. Illegitimate transcription: its use in the study of inherited disease. Hum. Mutat.1(5), 357–360 (1992).
   PubMedGoogle Scholar
• Johnson PW, Burchill SA, Selby PJ. The molecular detection of circulating tumour cells. Br. J. Cancer72(2), 268–276 (1995).
   PubMed Web of Science ®Google Scholar
• Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin. Cancer Res.5(8), 1950–1960 (1999).
   PubMed Web of Science ®Google Scholar
• Ghossein RA, Carusone L, Bhattacharya S. Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas. Diagn. Mol. Pathol.8(4), 165–175 (1999).
   PubMedGoogle Scholar
• Ghossein RA, Osman I, Bhattacharya S et al. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagn. Mol. Pathol.8(2), 59–65 (1999).
   Google Scholar
• Smerage JB, Hayes DF. The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br. J. Cancer94(1), 8–12 (2006).
   PubMedGoogle Scholar
• Hu XC, Wang Y, Shi DR, Loo TY, Chow LW. Immunomagnetic tumor cell enrichment is promising in detecting circulating breast cancer cells. Oncology64(2), 160–165 (2003).
   PubMed Web of Science ®Google Scholar
• Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet338(8777), 1227–1229 (1991).
   PubMed Web of Science ®Google Scholar
• Ghossein RA, Coit D, Brennan M et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin. Cancer Res.4(2), 419–428 (1998).
   PubMed Web of Science ®Google Scholar
• Mocellin S, Del Fiore P, Guarnieri L et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int. J. Cancer111(5), 741–745 (2004).
   Web of Science ®Google Scholar
• Osella-Abate S, Savoia P, Quaglino P et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br. J. Cancer89(8), 1457–1462 (2003).
   Google Scholar
• Voit C, Kron M, Rademaker J et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J. Clin. Oncol.23(6), 1218–1227 (2005).
   Google Scholar
• Wascher RA, Morton DL, Kuo C et al. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J. Clin. Oncol.21(13), 2558–2563 (2003).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med.351(8), 781–791 (2004).
   PubMed Web of Science ®Google Scholar
• Iakovlev VV, Goswami RS, Vecchiarelli J, Arneson NC, Done SJ. Quantitative detection of circulating epithelial cells by Q-RT-PCR. Breast Cancer Res. Treat.107(1), 145–154 (2007).
   Google Scholar
• Schmidt-Kittler O, Ragg T, Daskalakis A et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA100(13), 7737–7742 (2003).
   PubMed Web of Science ®Google Scholar
• Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res.12(14 Pt 1), 4218–4224 (2006).
   PubMed Web of Science ®Google Scholar
• Wulfing P, Borchard J, Buerger H et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res.12(6), 1715–1720 (2006).
   PubMed Web of Science ®Google Scholar
• Ulmer A, Schmidt-Kittler O, Fischer J et al. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin. Cancer Res.10(2), 531–537 (2004).
   Google Scholar
• Bozionellou V, Mavroudis D, Perraki M et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res.10(24), 8185–8194 (2004).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Kattan MW, Song W et al. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res.63(18), 5874–5878 (2003).
   Google Scholar
• Mikulowska-Mennis A, Taylor TB, Vishnu P et al. High-quality RNA from cells isolated by laser capture microdissection. Biotechniques33(1), 176–179 (2002).
   Google Scholar
• Faury D, Nantel A, Dunn SE et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J. Clin. Oncol.25(10), 1196–1208 (2007).
   PubMed Web of Science ®Google Scholar
• Gebauer G, Krones-Herzig A, Glinskii AB, Glinsky GV. Identification of genes associated with tumor progression using microarrays. Anticancer Res.25(3A), 1477–1482 (2005).
   PubMed Web of Science ®Google Scholar
• Glinsky GV. Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle4(9), 1171–1175 (2005).
   PubMed Web of Science ®Google Scholar
• Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest.115(6), 1503–1521 (2005).
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat. Genet.33(1), 49–54 (2003).
   PubMed Web of Science ®Google Scholar
• Smirnov DA, Foulk BW, Doyle GV et al. Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res.66(6), 2918–2922 (2006).
   PubMed Web of Science ®Google Scholar
• Klein CA, Blankenstein TJ, Schmidt-Kittler O et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet360(9334), 683–689 (2002).
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Muller V, Stahmann N, Pantel K. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann. NY Acad. Sci.1022, 25–32 (2004).
   PubMed Web of Science ®Google Scholar
• Muller V, Pantel K. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res.6(6), 258–261 (2004).
   Google Scholar
• Kraus J, Pantel K, Pinkel D, Albertson DG, Speicher MR. High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer36(2), 159–166 (2003).
   PubMed Web of Science ®Google Scholar
• Steemers FJ, Chang W, Lee G et al. Whole-genome genotyping with the single-base extension assay. Nat. Methods3(1), 31–33 (2006).
   PubMed Web of Science ®Google Scholar
• Gunderson KL, Kuhn KM, Steemers FJ et al. Whole-genome genotyping of haplotype tag single nucleotide polymorphisms. Pharmacogenomics7(4), 641–648 (2006).
   Web of Science ®Google Scholar
• Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS. A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet.37(5), 549–554 (2005).
   PubMed Web of Science ®Google Scholar
• Fan JB, Chee MS, Gunderson KL. Highly parallel genomic assays. Nat. Rev. Genet.7(8), 632–644 (2006).
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C, Brouillet JP, Fabbro M et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J. Immunol. Methods299(1–2), 177–188 (2005).
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C, Vendrell JP, Pelle O et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin. Chem.53(3), 537–539 (2007).
   PubMed Web of Science ®Google Scholar
• Koch M, Kienle P, Hinz U et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann. Surg.241(2), 199–205 (2005).
   PubMed Web of Science ®Google Scholar
• Bessa X, Pinol V, Castellvi-Bel S et al. Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated on for cure. Ann. Surg.237(3), 368–375 (2003).
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann. Surg.232(1), 58–65 (2000).
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Kakolyris S et al. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int. J. Cancer108(4), 620–627 (2004).
   Google Scholar
• Stathopoulou A, Vlachonikolis I, Mavroudis D et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol.20(16), 3404–3412 (2002).
   PubMed Web of Science ®Google Scholar
• Jotsuka T, Okumura Y, Nakano S et al. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery135(4), 419–426 (2004).
   Google Scholar
• Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van’t Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br. J. Cancer88(7), 1091–1094 (2003).
   PubMed Web of Science ®Google Scholar
• Pierga JY, Bonneton C, Vincent-Salomon A et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res.10(4), 1392–1400 (2004).
   PubMed Web of Science ®Google Scholar
• de la Taille A, Olsson CA, Buttyan R et al. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int. J. Cancer84(4), 360–364 (1999).
   Google Scholar
• Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J. Clin. Oncol.21(3), 490–495 (2003).
   Google Scholar
• Thomas J, Gupta M, Grasso Y et al. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J. Clin. Oncol.20(15), 3213–3218 (2002).
   Google Scholar
• Domingo-Domenech J, Molina R, Castel T et al. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon – comparison with tyrosinase rt-PCR. Oncology68(4–6), 341–349 (2005).
   Google Scholar
• Gogas H, Kefala G, Bafaloukos D et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer87(2), 181–186 (2002).
   PubMed Web of Science ®Google Scholar
• Proebstle TM, Jiang W, Hogel J et al. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br. J. Cancer82(1), 118–123 (2000).
   PubMed Web of Science ®Google Scholar
• Reynolds SR, Albrecht J, Shapiro RL et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin. Cancer Res.9(4), 1497–1502 (2003).
   PubMed Web of Science ®Google Scholar
• Hoon DS, Bostick P, Kuo C et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res.60(8), 2253–2257 (2000).
   PubMed Web of Science ®Google Scholar
• Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J. Clin. Oncol.17(8), 2562–2571 (1999).
   PubMed Web of Science ®Google Scholar
• Schmidt H, Sorensen BS, Fode K, Nexo E, von der Maase H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res.15(5), 409–416 (2005).
   Google Scholar
• Palmieri G, Ascierto PA, Perrone F et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J. Clin. Oncol.21(5), 767–773 (2003).
   Web of Science ®Google Scholar